Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
Onderliggende oorzaken TIA en minor stroke beïnvloeden risico ernstig vasculair event
dec 2023 | Atherosclerose, Neuro-vasculair